Format

Send to

Choose Destination
See comment in PubMed Commons below
Antimicrob Agents Chemother. 2009 May;53(5):1727-34. doi: 10.1128/AAC.00729-08. Epub 2009 Feb 17.

Novel inhibitor of Plasmodium histone deacetylase that cures P. berghei-infected mice.

Author information

1
Department of Biochemistry and Molecular Biology, Georgetown University Medical Center, Washington, DC 20057, USA.

Abstract

Histone deacetylases (HDAC) are potential targets for the development of new antimalarial drugs. The growth of Plasmodium falciparum and other apicomplexans can be suppressed in the presence of potent HDAC inhibitors in vitro and in vivo; however, in vivo parasite suppression is generally incomplete or reversible after the discontinuation of drug treatment. Furthermore, most established HDAC inhibitors concurrently show broad toxicities against parasites and human cells and high drug concentrations are required for effective antimalarial activity. Here, we report on HDAC inhibitors that are potent against P. falciparum at subnanomolar concentrations and that have high selectivities; the lead compounds have mean 50% inhibitory concentrations for the killing of the malaria parasite up to 950 times lower than those for the killing of mammalian cells. These potential drugs improved survival and completely and irreversibly suppressed parasitemia in P. berghei-infected mice.

PMID:
19223622
PMCID:
PMC2681568
DOI:
10.1128/AAC.00729-08
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire Icon for PubMed Central
    Loading ...
    Support Center